{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:16:17Z","timestamp":1791944177106,"version":"4.3.4"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Chronic thromboembolic pulmonary hypertension (CTEPH) is a subtype of pulmonary hypertension characterized by organized thrombi inside the pulmonary vasculature, leading to an increase in pulmonary artery pressure. CTEPH is seen in about 3\u20134% of patients with acute pulmonary embolism and is associated with poor outcomes. Apart from surgical intervention, lifelong anticoagulation is the mainstay of CTEPH management. Traditionally, CTEPH is managed with vitamin-K antagonists (VKA); however, direct oral anticoagulants (DOACs) are recently gaining popularity. However, the current literature comparing DOACs versus VKAs in CTEPH has inconsistent results. An electronic search of the major bibliographic databases was performed to retrieve studies comparing DOACs versus VKAs in CTEPH patients. For dichotomous outcomes, the odds ratio (ORs) with 95% confidence intervals (CI) were pooled using the DerSimonian and Laird random-effects model to generate forest plots. Statistical significance was considered at <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05. Ten studies were included with 3936 patients (1269 in the DOAC group and 2667 in the VKA group). Treatment with DOAC was associated with no statistically significant difference in the risk of all-cause mortality (OR, 0.78; 95% CI, 0.35\u20131.71; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.53), venous thromboembolism (OR, 1.19; 95% CI, 0.59\u20132.40; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.63), major bleeding (OR, 0.68; 95% CI, 0.38\u20131.22; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.20), and clinically relevant nonmajor bleeding (OR, 1.22; 95% CI, 0.80\u20131.86; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.37). Our analysis demonstrates that DOACs are noninferior to VKAs in terms of their safety and outcomes profile in CTEPH. Further trials are needed to evaluate more robust evidence and to compare additional outcomes.<\/jats:p>","DOI":"10.1097\/crd.0000000000000735","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T21:13:01Z","timestamp":1717535581000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Safety and Outcomes with Direct Oral Anticoagulants Versus Vitamin-K Antagonists in Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review, Meta-Analysis, and Meta-Regression"],"prefix":"10.1097","author":[{"given":"Hritvik","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, All India Institute of Medical Sciences (AIIMS), Jodhpur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramez M.","family":"Odat","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mushood","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, All India Institute of Medical Sciences (AIIMS), Jodhpur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Goyal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seth GS Medical College and KEM Hospital, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Idrees","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Lahore General Hospital, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhant","family":"Passey","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Connecticut Health Center, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagriti","family":"Jha","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Connecticut Health Center, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janhvi","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, St Luke\u2019s Hospital, Chesterfield, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrey","family":"Gole","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Stanford University, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"key":"R1-20240817","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1016\/j.lpm.2015.10.010","article-title":"Chronic thromboembolic pulmonary hypertension.","volume":"44","author":"O\u2019Connell","year":"2015","journal-title":"Presse Med"},{"key":"R2-20240817","doi-asserted-by":"crossref","first-page":"F1000 Faculty Rev","DOI":"10.12688\/f1000research.18811.1","article-title":"The 6th world symposium on pulmonary hypertension: what\u2019s old is new.","volume":"8","author":"Condon","year":"2019","journal-title":"F1000Res"},{"key":"R3-20240817","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ccl.2020.02.001","article-title":"Right heart failure in pulmonary hypertension.","volume":"38","author":"Cassady","year":"2020","journal-title":"Cardiol Clin"},{"key":"R4-20240817","doi-asserted-by":"crossref","first-page":"195","DOI":"10.14797\/mdcj-12-4-195","article-title":"Epidemiology and pathophysiology of chronic thromboembolic pulmonary hypertension: risk factors and mechanisms.","volume":"12","author":"Medrek","year":"2016","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"R5-20240817","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1183\/09059180.00009111","article-title":"Risk factors for chronic thromboembolic pulmonary hypertension.","volume":"21","author":"Kim","year":"2012","journal-title":"Eur Respir Rev"},{"key":"R6-20240817","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1183\/16000617.00000815","article-title":"Pulmonary endarterectomy: the potentially curative treatment for patients with chronic thromboembolic pulmonary hypertension.","volume":"24","author":"Jenkins","year":"2015","journal-title":"Eur Respir Rev"},{"key":"R7-20240817","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1093\/ejcts\/ezt293","article-title":"Pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: an institutional experience.","volume":"44","author":"Yildizeli","year":"2013","journal-title":"Eur J Cardiothorac Surg"},{"key":"R8-20240817","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.4244\/EIJ-D-21-00230","article-title":"Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension: a multicentre registry.","volume":"17","author":"Darocha","year":"2022","journal-title":"EuroIntervention"},{"key":"R9-20240817","doi-asserted-by":"crossref","first-page":"100579","DOI":"10.1016\/j.blre.2019.05.003","article-title":"Indications and potential pitfalls of anticoagulants in pulmonary hypertension: would DOACs become a better option than VKAs?","volume":"37","author":"Margelidon-Cozzolino","year":"2019","journal-title":"Blood Rev"},{"key":"R10-20240817","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3390\/diagnostics12020235","article-title":"Chronic thromboembolic pulmonary hypertension: an update.","volume":"12","author":"Ruaro","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"R11-20240817","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS).","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"R12-20240817","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.repc.2021.09.023","article-title":"Evaluating the efficacy and safety of rivaroxaban as a warfarin alternative in chronic thromboembolic pulmonary hypertension patients undergoing pulmonary endarterectomy: a randomized clinical trial.","volume":"42","author":"Barati","year":"2023","journal-title":"Rev Port Cardiol"},{"key":"R13-20240817","doi-asserted-by":"crossref","first-page":"2045894019873545","DOI":"10.1177\/2045894019873545","article-title":"Real-life data of direct anticoagulant use, bleeding risk and venous thromboembolism recurrence in chronic thromboembolic pulmonary hypertension patients: an observational retrospective study.","volume":"10","author":"Sena","year":"2020","journal-title":"Pulm Circ"},{"key":"R14-20240817","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/jth.14649","article-title":"A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension.","volume":"18","author":"Bunclark","year":"2020","journal-title":"J Thromb Haemost"},{"key":"R15-20240817","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"key":"R16-20240817","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R17-20240817","doi-asserted-by":"crossref","first-page":"102237","DOI":"10.1016\/j.cpcardiol.2023.102237","article-title":"The impact of chronic total occlusion in non-infarct related arteries on patient outcomes following percutaneous coronary intervention for STEMI superimposed with cardiogenic shock: a pilot systematic review and meta-analysis.","volume":"49","author":"Goyal","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"R19-20240817","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R20-20240817","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R21-20240817","doi-asserted-by":"crossref","first-page":"102538","DOI":"10.1016\/j.cpcardiol.2024.102538","article-title":"Association between psoriasis and atrial fibrillation: a systematic review and meta-analysis.","volume":"49","author":"Jain","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"R22-20240817","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/biom.12817","article-title":"Quantifying publication bias in meta-analysis.","volume":"74","author":"Lin","year":"2018","journal-title":"Biometrics"},{"key":"R24-20240817","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.thromres.2023.07.002","article-title":"Safety and efficacy of direct oral anticoagulants in patients with chronic thromboembolic pulmonary hypertension.","volume":"229","author":"Benzidia","year":"2023","journal-title":"Thromb Res"},{"issue":"Suppl_1","key":"R25-20240817","first-page":"A15733","article-title":"Abstract 15733: comparison of efficacy and safety between direct oral anticoagulant and warfarin in patients with chronic thromboembolic pulmonary hypertension.","volume":"138","author":"Hayashi","year":"2018","journal-title":"Circulation"},{"key":"R26-20240817","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.thromres.2019.05.018","article-title":"Use of direct oral anticoagulants prevents increase in pulmonary vascular resistance and incidence of clinical worsening in patients with chronic thromboembolic pulmonary hypertension.","volume":"180","author":"Hosokawa","year":"2019","journal-title":"Thromb Res"},{"key":"R27-20240817","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.jtha.2023.03.036","article-title":"Long-term outcome of chronic thromboembolic pulmonary hypertension using direct oral anticoagulants and warfarin: a Japanese prospective cohort study.","volume":"21","author":"Hosokawa","year":"2023","journal-title":"J Thromb Haemost"},{"key":"R28-20240817","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1161\/CIRCULATIONAHA.123.067528","article-title":"A Multicenter, single-blind, randomized, warfarin-controlled trial of edoxaban in patients with chronic thromboembolic pulmonary hypertension: KABUKI Trial.","volume":"149","author":"Hosokawa","year":"2024","journal-title":"Circulation"},{"key":"R29-20240817","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.healun.2022.02.002","article-title":"Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension.","volume":"41","author":"Humbert","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"R30-20240817","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1007\/s00380-021-01799-x","article-title":"Evolution of patients with chronic thromboembolic pulmonary hypertension treated by balloon pulmonary angioplasty, according to their anticoagulant regimens.","volume":"36","author":"Ikeda","year":"2021","journal-title":"Heart Vessels"},{"key":"R31-20240817","doi-asserted-by":"crossref","first-page":"10760296231156414","DOI":"10.1177\/10760296231156414","article-title":"Retrospective analysis of direct-acting oral anticoagulants (DOACs) initiation timing and outcomes after thrombolysis in high- and intermediate-risk pulmonary embolism.","volume":"29","author":"Wolfe","year":"2023","journal-title":"Clin Appl Thromb Hemost"},{"key":"R32-20240817","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.thromres.2023.10.003","article-title":"Anticoagulation in chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis.","volume":"231","author":"Ishisaka","year":"2023","journal-title":"Thromb Res"},{"key":"R33-20240817","doi-asserted-by":"crossref","first-page":"102377","DOI":"10.1016\/j.cpcardiol.2024.102377","article-title":"Clinical outcomes between direct oral anticoagulants versus vitamin K antagonists in chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis.","volume":"49","author":"Salazar","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"R34-20240817","doi-asserted-by":"crossref","first-page":"101232","DOI":"10.1016\/j.cpcardiol.2022.101232","article-title":"Head-to-head comparison between direct oral anticoagulants and vitamin k antagonists for chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis.","volume":"48","author":"Burmeister","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"R35-20240817","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.amjcard.2023.10.017","article-title":"Meta-Analysis comparing direct oral anticoagulants versus vitamin K antagonists in patients with chronic thromboembolic pulmonary hypertension.","volume":"210","author":"Kido","year":"2024","journal-title":"Am J Cardiol"},{"key":"R36-20240817","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12325-022-02333-9","article-title":"Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism: a narrative review.","volume":"40","author":"Ballestri","year":"2023","journal-title":"Adv Ther"},{"key":"R37-20240817","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex.","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"key":"R38-20240817","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s11239-013-0899-7","article-title":"Assessing bleeding risk in patients taking anticoagulants.","volume":"35","author":"Shoeb","year":"2013","journal-title":"J Thromb Thrombolysis"},{"key":"R39-20240817","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1183\/09031936.00040714","article-title":"Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review.","volume":"45","author":"Klok","year":"2015","journal-title":"Eur Respir J"},{"key":"R40-20240817","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11239-019-01954-2","article-title":"Direct oral anticoagulants: a review on the current role and scope of reversal agents.","volume":"49","author":"Chaudhary","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"R41-20240817","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ahj.2015.03.017","article-title":"Patients\u2019 time in therapeutic range on warfarin among US patients with atrial fibrillation: results from ORBIT-AF registry.","volume":"170","author":"Pokorney","year":"2015","journal-title":"Am Heart J"},{"key":"R42-20240817","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1186\/1756-0500-7-891","article-title":"Evaluation of time in therapeutic range in anticoagulated patients: a single-center, retrospective, observational study.","volume":"7","author":"Caldeira","year":"2014","journal-title":"BMC Res Notes"},{"issue":"2 Suppl","key":"R43-20240817","doi-asserted-by":"crossref","first-page":"e326S","DOI":"10.1378\/chest.11-2298","article-title":"Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.","volume":"141","author":"Douketis","year":"2012","journal-title":"Chest"},{"key":"R44-20240817","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/phar.2158","article-title":"Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010-2017.","volume":"38","author":"Zhu","year":"2018","journal-title":"Pharmacotherapy"},{"key":"R45-20240817","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the heart rhythm society.","volume":"74","author":"January","year":"2019","journal-title":"J Am Coll Cardiol"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000735","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T17:06:33Z","timestamp":1723914393000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":43,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000735","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,4]]}}}